Ellis, Ian O., Dowsett, M., Bartlett, J., Walker, Rosemary A., Cooke, T., Gullick, William J., Gusterson, B., Mallon, E., Lee, P. Barrett (2000) Recommendations for HER2 testing in the UK. Journal of Clinical Pathology, 53 (12). pp. 890-892. ISSN 0021-9746. (doi:10.1136/jcp.53.12.890) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:16065)
| The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. | |
| Official URL: http://dx.doi.org/10.1136/jcp.53.12.890 |
Abstract
Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin(R)), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.1136/jcp.53.12.890 |
| Uncontrolled keywords: | HER2 • breast cancer • Herceptin |
| Subjects: |
R Medicine > RB Pathology R Medicine > RC Internal medicine > RC254 Neoplasms. Tumors. Oncology |
| Divisions: | Divisions > Division of Natural Sciences > Biosciences |
| Depositing User: | O.O. Odanye |
| Date Deposited: | 19 May 2009 00:59 UTC |
| Last Modified: | 05 Nov 2024 09:50 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/16065 (The current URI for this page, for reference purposes) |
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
